Former Lilly neuroscience chief heads to J&J

Tuesday, March 8, 2011 11:08 AM

Former Eli Lilly neuroscience chief David Bredt’s recent resignation was not due to the company's setbacks in that field, according to FierceBiotech. Bredt has landed a new job in the neuroscience research group at Johnson & Johnson, which is looking to advance its own pipeline of drugs for Alzheimer's and other neurological diseases.

Bredt was sought after by the global head of neuroscience at J&J, Husseini Manji. "We think the science is exploding, and we can enhance our efforts," Manji said in an interview with the Wall Street Journal Health Blog.

Bredt will oversee development of new drugs and "ways for measuring their worth, such as biomarkers and animal models for testing the molecules," according to the WSJ report.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs